



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61F 2/28, A61L 31/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/15694</b> <b>(43) International Publication Date:</b> 19 August 1993 (19.08.93)
<b>(21) International Application Number:</b> PCT/US93/01315 <b>(22) International Filing Date:</b> 12 February 1993 (12.02.93) <b>(30) Priority data:</b> 07/837,401                      14 February 1992 (14.02.92)    US <b>(71) Applicant:</b> BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). <b>(72) Inventors:</b> ATHANASIOU, Kypriacos, A. ; 17105 Lone Cypress, Helotes, TX 78023 (US). BOYAN, Barbara, D. ; 6851 Callaghan Road, San Antonio, TX 78229 (US). <b>(74) Agent:</b> MEYERTONS, Eric, B.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		<b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MULTI-PHASE BIOERODIBLE IMPLANT/CARRIER AND METHOD OF MANUFACTURING AND USING SAME  <div data-bbox="521 1110 1263 1705" data-label="Image"> </div>		
<b>(57) Abstract</b>  <p>A carrier and method of manufacturing and using the same is provided for receiving supporting replenished tissue growing into a diseased or damaged area within a physiological system. The carrier can be implanted in the interface region between tissue having different mechanical properties to support the growth and regeneration of differing types of tissue within the region. The carrier includes bioerodible polymeric material having differing mechanical properties such as porosity, stiffness and compressibility.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

Description

5                   **MULTI-PHASE BIOERODIBLE IMPLANT/CARRIER AND  
METHOD OF MANUFACTURING AND USING SAME**

BACKGROUND OF THE INVENTION

1.   Field of the Invention

10           This invention relates to a multi-phase  
biodegradable implant/carrier (carrier) and a method for  
manufacturing and using the carrier in a physiological  
system to receive, induce and support subdermal tissue.

15   2.   Description of Relevant Art

          Devices used for treating and repairing damaged or  
defective tissue are well-known in the art. Whenever  
damage to tissue occurs, the tissue must be supported in  
a fairly stable condition as it is being regrown. Some  
20   structural types of tissue such as bone can be regrown  
naturally provided the trauma area is not significantly  
disrupted during the healing process. Outer supports  
such as a cast or sling can be used to secure the trauma  
area. Inner supports such as rods or pins may also be  
25   used in severe cases.

          If the damaged tissue region has low cellular  
density or lacks vasculature, as in articular cartilage,  
the healing process can sometimes last several months,  
30   years or may not occur whatsoever. If inner support pins  
are used, they require surgical implantation and, after  
several months or years, the pins often need to be  
surgically removed. Surgically implanting and removing  
support pins presents undue shock or trauma to the  
35   patient's system. Moreover, once the internal supports  
are removed, a hole or void is left in the region which  
must then be naturally filled with growing tissue to

-2-

fully complete the healing process. In the interim, the hole or void may leave the tissue prone to subsequent damage or breakage.

5

# SUMMARY OF THE INVENTION

The problems outlined above are in large part solved by the carrier of the present invention. That is, the carrier hereof provides convenient access for tissue  
10 ingrowth into and within the carrier's body. These sites allow tissue to invade the carrier's outer surface through growth channels (pores). These pores exist for promoting and receiving regenerated or resurfaced tissue. The carrier of the present invention can be implanted  
15 into a physiological system at a location adjoining two dissimilar types of tissue, e.g., cartilage and bone. The carrier of the present invention may also be implanted in other types of support or vascular tissues, e.g., at ligament and tendon insertion sites, in growth  
20 plate, at the periosteum-bone interface, and in hyaline cartilage and adjacent tissues, etc.

The tissue carrier of the present invention includes bioerodible polymeric material which substantially or  
25 completely dissolves over a period of time when exposed to aqueous fluids. During the time in which the carrier dissolves, growing tissue enters the access locations thereby providing a "scaffold" into which rapid tissue regeneration can occur in the damaged or diseased area.  
30 The carrier is particularly appropriate for promoting healing in tissue areas which do not heal easily. The dissolvable carrier provides interim support to the tissue area while tissue is being regenerated. Accordingly, the carrier of the present invention  
35 presents a bioerodible scaffold-type network for promoting, supporting and receiving the regeneration of diseased or damaged tissue. Thus the patient is not

-3-

subjected to undue trauma or risk associated with conventional internal rods or pins, or other non-degradable materials. In addition, wounds which would otherwise not heal with normal tissue are able to do so.

5

Broadly speaking, one embodiment of the present invention contemplates a carrier comprising at least two bioerodible polymeric materials having dissimilar mechanical properties arranged proximate to each other. The two bioerodible polymeric materials are capable of being placed into a physiological system adjoining two dissimilar types of tissue. Each polymeric material may also include an enzyme or other agents which may enhance material degradation. The carrier may also contain one or more growth factors, or other agents, which promote differentiation and growth of normal tissue. Enzymes, growth factors or other agents in one material can be mixed in different proportion to these additives in the other material to produce differing amounts of bioerosion or tissue repair depending upon the application desired. Each polymeric material has a variable degree of porosity or pore sizes into which tissue can enter and possibly adhere temporarily.

25 In another embodiment, the carrier of the present invention is capable of being subdermally implanted as a tissue support system. Preferably, the carrier can be implanted at an interface region between two dissimilar types of tissue. At least a portion of the carrier includes a first material having access sites for receiving growth of a first type of tissue. In addition, the carrier includes a second material having access sites for receiving growth of a second type of tissue. Once the carrier is implanted, the first material resides substantially within the first type of tissue and the second material resides substantially within the second type of tissue. According to one aspect of the

-4-

invention, access sites within the first material  
comprise pores extending into and within the first  
material and access sites within the second material  
comprise pores extending into and within the second  
5 material.

The present invention also contemplates a method for  
implanting a carrier within a physiological system  
including a bioerodible carrier having a first  
10 bioerodible polymeric material bonded to a second  
bioerodible polymeric material. For example, in the case  
of articular cartilage and bone, a hole may be bored  
through skin, underlying cartilage and into a bone  
thereby providing a passage into which the carrier can be  
15 implanted. Once placed, the first material of the  
carrier resides substantially within the bone and the  
second material resides substantially within the  
cartilage. The skin can be sutured over the carrier to  
prevent infection from entering the tissue area.

20

The present invention additionally contemplates a  
method for manufacturing a bioerodible carrier comprising  
solubilizing a polymer into a viscous form and then  
extracting substantial amounts of solvents from the  
25 viscous polymer to form pores within the resulting  
modified polymer. Internal pores within the modified  
polymer provide access locations along the outer surface  
of the carrier. A plurality of larger passages can also  
be mechanically placed within the modified polymer to  
30 increase the number of access locations. A second  
modified polymer can be added to a first modified polymer  
by bonding together the first and second polymers within  
a mold subjected to pressure-curing. Additional modified  
polymers can also be added.

35

-5-

BRIEF DESCRIPTION OF THE DRAWINGS

Other features and advantages of the invention will become apparent upon reading the following detailed description and upon reference to the accompanying drawings in which:

Fig. 1 is a perspective view of a two-phase carrier according to the present invention;

10

Fig. 1A is a cross-sectional view along plane A-A of Fig. 1;

Fig. 1B is a cross-sectional view along plane B-B of Fig. 1;

15

Fig. 2 is a cross-sectional view of an example of a physiological system prepared for implantation of a tissue carrier according to the present invention;

20

Fig. 3 is a cross-sectional view of an example of a physiological system implanted with a tissue carrier according to the present invention; and

Fig. 4 is a flow diagram of steps taken to produce a two-phase carrier according to the present invention.

25

While the invention is susceptible to various modifications and alternative forms, a specific embodiment thereof has been shown by way of example in the drawings and will herein be described in detail. It should be understood, however, that the drawings are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the pending claims.

30

35

DETAILED DESCRIPTION OF THE INVENTION

Turning now to the drawings, a carrier 10 is illustrated in Fig. 1 comprising a first bioerodible polymeric material 14 and a second bioerodible polymeric material 12. First material 14 and second material 12 are preferably made from a copolymer-based material of polyglycolic acid (PLG) and polylactic acid (PLA) in a 50/50 concentration of each. Also present in the PLA/PLG copolymer material may be an enzyme homogeneously dispersed within the copolymer which may enhance the degradation of the polymeric substance. Degradable polymeric substances useable in the present invention are frequently found in the general categories commonly known as polyesters, polyamides, polypeptides, or polysaccharides. Certain typical enzyme-degradable polymeric substances have long been used as biodegradable materials for sutures, for example. These typical degradable materials include alkylhydroxylic acids including, for example, the polyesters of monomeric units such as lactic acid, glycolic acid, hydroxypropionic acid, hydroxybutyric acid and combinations thereof. Lactic acid and glycolic acid are most commonly used for this purpose and preferably used in the present invention. Polymer of lactic acid (PLA) and glycolic acid (PGA) are well known in the art as described in U.S. Patent No. 3,991,776 (herein incorporated by reference).

Enzymes useable in the practice of the present invention are of a wide variety but most frequently are proteases or hydrolases with ester-hydrolyzing capabilities. Such enzymes include proteinase K, bromelaine, pronase E, cellulase, dextranase, elastase, plasmin streptokinase, trypsin, chymotrypsin, papain, chymopapain, collagenase, subtilisin, chlostridopeptidase



-7-

A, ficin, carboxypeptidase A, pectinase, pectinesterase, an oxidoreductase or an oxidase.

5 The ability of naturally occurring enzymes to  
degrade polymeric substances or materials are known in  
the art. See, e.g., Williams, D.F., "Some Observations  
on the Role of Cellular Enzymes in the *In-Vivo*  
Degradation of Polymers," Corrosion and Degradation of  
Implant Materials, ASTM STB 684, American Society for  
10 Testing and Materials, 1979, pp. 61-75.

A ratio of 50% PLA and 50% PLG suitable for  
materials 12 and 14 of the present invention can also be  
implanted with growth factors (e.g., transforming growth  
15 factor-beta) or other forms of therapeutic agents such as  
steroids or hormones for actively increasing the growth  
rate of the tissue area into which carrier 10 is capable  
of being placed. Dispersing therapeutic agents within a  
polymeric material is known in the art and generally  
20 described by Langer, R., "Controlled Release: A New  
Approach to Drug Delivery," *Technology Review*, April  
1981, pp. 26-34. Generally speaking, the therapeutic  
agent is homogeneously dispersed and entrapped in the  
polymeric material such that release of the agent is  
25 dependent upon the rate at which fluid diffuses through  
the polymer material. An example of therapeutic agents  
erodibly released at a controlled rate to surrounding  
tissue is described in U.S. Patent No. 4,346,709 (herein  
incorporated by reference).

30 Referring to Fig. 1, first material 14 is bonded to  
second material 12, wherein material 14 includes a body  
having dissimilar mechanical properties from material 12.  
Materials 14 and 12 may both include enzymes and  
35 therapeutic agents in addition to numerous pores 16 and  
18 formed within first material 14 and second material  
12, respectively. Pore size varies depending upon the

-8-

process by which materials 12 and 14 are processed. Preferably, porosity within each material 12 or material 14 is more than 50% of the respective material volumetric area. Moreover, pore size can range between 50 and 200  
5  $\mu\text{m}$ . However, it is to be appreciated that pore density as well as pore size can vary outside these ranges depending upon the particular manufacturing process chosen, as described herein below. Preferably, material 12 is manufactured having a porosity which generally  
10 matches the porosity of the surrounding tissue into which carrier 10 is placed. Similarly, material 14 can be manufactured to a porosity substantially equal to its surrounding tissue. Thus, depending upon the specific application desired, the method of manufacturing carrier  
15 10 can be quickly and easily altered to contain pores of varying size and density.

Carrier 10 can also be perforated with a plurality of passages 20 extending partially or completely through  
20 carrier 10. Passages 20 are suitably placed to provide additional sites or locations into or onto which surrounding tissue can enter and/or temporarily bond. Passages 20 are generally larger in diameter than pores 16 or 18 and can be mechanically placed as described  
25 below.

Referring to Fig. 1A, a cross-sectional view of material 12 is shown having numerous access sites or locations formed by pores 16 and passages 20. As shown  
30 by the comparisons of Figs. 1A and 1B, material 14 is less porous than material 12 to substantially match a less porous tissue surrounding material 14 than the tissue surrounding material 12. Moreover, material 12 and 14 can be manufactured having mechanical properties  
35 such as stiffness and compressibility, in addition to porosity, to substantially match the mechanical

-9-

properties of surrounding tissue into which material 12 and 14 is placed.

5 Tissue carrier 10, having materials 12 and 14 of possibly different mechanical properties, is particularly adapted for placement into a juncture region adjoining tissue areas having dissimilar mechanical properties. Materials within carrier 10 correspondingly can be processed to have mechanical properties such as porosity, stiffness, etc. to substantially match the properties of the tissue juncture region after implantation. As illustrated in Fig. 2, a physiological environment into which carrier 10 can be placed, includes, but is not limited to, a human or animal articular cartilage and underlying bone. Carrier 10 is shown insertable into a bore 22 through skin 24, through underlying cartilage 26 and into bone 28. Alternatively, carrier 10 can be placed entirely within bone 28 to provide structural support to the juncture region between cortical bone and cancellous bone. Accordingly, bore 22 and implantable carrier 10 can be placed into any physiological system having a juncture between dissimilar types of tissue. As used herein, "tissue" includes cellular material found subdermally anywhere within an animal or human anatomy. Any region joining two dissimilar types of tissue (i.e., bone, cartilage, tendon, skin, ligament, cementum, etc.) can be implanted with the bonded dissimilar materials 12 and 14 of carrier 10. By bonding each material together and implanting the combination within a tissue juncture, carrier 10 ensures the tissue juncture remains together during the repair process, which may help to promote rapid healing.

35 Fig. 3 illustrates carrier 10 fully implanted within dissimilar tissue regions, e.g., cartilage 26 and bone 28. After inserting carrier 10 through hole 22, outer skin 24 is sutured over the bore passage to prevent

-10-

infection from entering the underlying region. As can be appreciated from the present invention, carrier 10 is produced in any desired shape with differing mechanical characteristics depending upon the size and composition of the target area. In this example, carrier 10 is cylindrical in shape having an outer diameter generally matching the inner diameter of a bore or hole 22 created in the region of interest. However, other shapes can be produced and inserted into the hole. Regardless of the shape used, the carrier can expand to match the internal cavity or bore size prior to or during the bioerodible process. Still further, the proportionate sizes of material 12 and 14 can be varied depending upon the relative location of carrier 10 in relation to the interface region. For example, cartilage 26 may be thicker than that indicated in Fig. 3 such that its thickness would be equal to or greater than the bore 22 depth into bone 28. Consequently, material 14 can be made larger or thicker than material 12 to correspond with the relative shift in boundary between cartilage 26 and bone 28.

Bone 28 generally presents a less porous and stiffer material than overlying cartilage 26. Therefore, as shown in Fig. 3, pores 18 can be made relatively smaller than pores 16. Accorded access sites or locations into pores 18 and 16 are dissimilar to generally match surrounding bone 28 and tissue 26, respectively. During the time in which bone 28 and cartilage 26 tissue regenerate and grow into the damaged region partially replaced with carrier 10 and pores 18 and 16, respectively, carrier 10 maintains a somewhat rigid support structure. As the structure of carrier 10 gradually erodes or dissolves, regeneration of tissue takes place which replaces the structural support lost during erosion. Accordingly, the present invention serves to provide better anchorage of regenerated tissue

-11-

in the damaged or defective region and also provides a temporary support structure which need not be subsequently removed as in conventional rods and pins. The bioerodible carrier 10 is particularly useful in  
5     juncture regions where slow healing occurs due to lack of vasculature or cell population.

As illustrated in Fig. 4, the method by which carrier 10 is produced is fairly simple and does not  
10     require expensive equipment. In particular, a PLA/PLG mixture of polymer-based starting material 30 is preferably used in solid form as the starting material. The starting polymer-based solid form material may be purchased through, for example, Birmingham Polymers,  
15     Inc., Birmingham, Alabama. The starting material can be placed in a mixing bowl and solubilized or dissolved 32 in a liquid such as acetone to produce a liquid form of PLA/PLG polymer. The liquid form can then be  
20     precipitated 34 with a suitable solvent such as ethanol to remove part of the liquid phase leaving a fairly viscous mixture of material. This material can be set aside and designated as first material and then the solubilized and precipitated steps 32 and 34 repeated for a second material. The first material may, for example,  
25     be used to produce material 14 and the second material used to produce material 12 as shown in Figs. 1-3.

Depending upon the amount of porosity, stiffness or compressibility of the finished product, more or less  
30     acetone and/or ethanol can be utilized. For example, if more acetone is used, the finished product may have a higher porosity, less compressive stiffness and less resulting viscosity. If material 12 is to be placed adjacent to cartilage 26, then a suitable viscosity of  
35     the product used to form material 12 may be approximately 0.43 dl/gm (average molecular weight 12-15 kD). Conversely, if material 14 is to be placed adjacent bone,

-12-

then the target viscosity of product used to form material 14 may be approximately 0.53 dl/gm (average molecular weight 60-70 kD). Depending upon the mechanical characteristics of tissue surrounding the  
5 implanted carrier 10, more or less dissolving and/or precipitating agent can be added to the starting material so that the resulting product has substantially similar mechanical characteristics to the surrounding tissue.

10 The resulting product receives its mechanical properties and desired porosity by placing the product in a suitable vacuum of approximately 20m Torr for 30 minutes to help dry the material to its desired state. More or less vacuum pressure for longer or shorter  
15 periods of time can be used to increase or decrease the porosity of the material. A pressurized chamber with regulated temperature is suitable to effectively drive out most of the dissolving and precipitating agents to render the product mechanically compatible with the  
20 target tissue area into which it is capable of being placed.

Once the product has been pressurized and pores imparted within the bulk material, the material is placed  
25 into a mold. Preferably, the mold is made of a Teflon® material having one or more wells adapted to receive the material in its modified form. Each well of the mold is shaped depending upon the particular geometric configuration required of carrier 10. Either first  
30 material 14 or second material 12 is initially placed into the mold and a plug also inserted into the mold. The plug can be actuated against the material thereby compressing 36 the material between the plug and surrounding walls of the mold.

35

The plug can contain a plurality of elongated tines which penetrate at least partially into the material

-13-

forming passages 20 which extend along the longitudinal axis of, e.g., a cylindrical carrier configuration. Duration of the compression by a plug can vary depending upon the resulting mechanical properties desired. More  
5 compression, for example, will create a less porous, less compressible material suitable for placement in heavier, denser tissue such as cortical bone, whereas less compression will produce a more porous, more compressible material suitable for placement in lighter tissue such as  
10 cartilage or ligaments. If bone is the target area into which first material 14 is placed, then pressure cure via the plug can last for approximately 48 hours in room temperature. However, the amount of cure can change drastically depending upon the mechanical properties  
15 desired.

Another batch of material or, e.g., second material 12 can be added 38 to the mold on top of and adjacent to, e.g., the first material 14. The first and second  
20 material 14 and 12 are then pressure-cured 40 via the plug having longitudinal tines placed therein. Pressure-cure can vary drastically, however, a preferred duration is approximately 48 hours, similar to the cure period of previous material. After the combination of first and  
25 second material 14 and 12 is fully cured within the mold, the resulting carrier 10 is removed or extracted 42 from the mold and perforations placed into the carrier substantially perpendicular to the passages created by the tines. A preferred method of placing the  
30 perforations or lateral passages 20 into carrier 10 would include rolling carrier 10 on a special surface which creates passages of approximately 1.5 mm in diameter.

The resulting carrier 10 includes first and second  
35 material 14 and 12 molded or bonded together in a fairly rigid, yet porous multi-phase structure which is then finally lyophilized for 48 hours at 20 m Torr and 40° C

-14-

to remove remnants of the solvents. The first material 14 will be macro- and micro-porous but may be stiffer than material 12 due to it possibly having higher molecular weight, longer curing, and higher compressibility. First material 14 preferably interfaces with a more dense tissue such as subchondral bone to provide fixation of growing bone tissue, whereas second material 12 interfaces with less dense tissue such as cartilage.

10

As shown in Figs. 2 and 3, carrier 10 is insertable as a press-fit in the osteochondral defect region. The swelling characteristics of the bioerodible material 14 and 12 is expected to improve retention of carrier 10 within the defect region. Comparable mechanical properties of materials 14 and 12 to that of surrounding tissue avoids stress concentrations during joint articulation. By matching mechanical characteristics such as porosity, exchange of nutrients from the tissue into carrier 10 is provided as though normal growth patterns occur. Confocal laser scanning micrographs of carrier 10 may illustrate carrier 10 having pores 16 and 18 of varying sizes, but which are generally microporous and may be interconnected throughout the cross-sectional area of the material.

The foregoing description of the present invention has been directed to particular embodiments. It will be apparent, however, to those skilled in the art, that modifications and changes in both the carrier and the method of making and using the carrier can be made without departing from the scope and spirit of the invention. For example, curing times and pressures can vary as well as the relative concentrations of the dissolving and precipitating agents. Further, carrier 10 can be made of varying sizes and shapes depending upon the appropriate environment into which it is placed.



-15-

Still further, varying amounts of enzymes or other agents can be incorporated into the polymeric material to vary the erodibility of the material depending upon the amount of healing time required. Finally, varying amounts of growth factors, hormones, or other agents, can be incorporated into the polymeric material to vary the ability of the implant to induce, promote, and support tissue in growth and repair. Therefore, it is the intention in the following claims to cover all such equivalent modifications and variations which fall within the true spirit and scope of this invention.

-16-

CLAIMS

1. A carrier, comprising:

5 at least two bioerodible polymeric materials having  
dissimilar mechanical properties arranged  
proximate each other;

10 said bioerodible polymeric materials are capable of  
being placed into a physiological system  
adjoining at least two dissimilar types of  
tissue.

15 2. The carrier as recited in claim 1, wherein each said  
material comprises an enzyme or other agent to enhance  
degradation of said material.

20 3. The carrier as recited in claim 1, wherein each said  
material comprises a growth factor, a hormone or other  
agent to induce, promote or support tissue ingrowth and  
repair.

25 4. The carrier as recited in claim 2, wherein said  
enzyme is mixed in varying proportion to degrade each  
said material within a variable time period.

30 5. The carrier as recited in claim 1, wherein said at  
least two materials are molded adjacent to each other.

35 6. The carrier as recited in claim 1, wherein said  
mechanical properties include stiffness, compressibility  
and porosity.

-17-

7. The carrier as recited in claim 1, wherein each said material comprises a plurality of access sites arranged along the external surface of said material to receive  
5 tissue having mechanical properties substantially similar to the mechanical properties of respective said material.

8. An implantable tissue support system comprising:  
10 a first bioerodible polymeric material;  
a second bioerodible polymeric material molded adjacent said first material; and  
15 said first material and said second material are capable of being implanted into a physiological system at the interface region between a first type of tissue and a second type of tissue,  
20 wherein said first material includes access sites for receiving growth of said first type of tissue and said second material includes access sites for receiving growth of said second type of tissue.

25 9. The system as recited in claim 8, wherein said first material resides substantially within said first tissue.

30 10. The system as recited in claim 8, wherein said second material resides substantially within said second tissue.

-18-

11. The system as recited in claim 8, wherein said first material includes mechanical properties dissimilar from mechanical properties of said second material.

5

12. The system as recited in claim 8, wherein said access sites within said first material comprise pores extending into said first material.

10

13. The system as recited in claim 8, wherein said access sites within said second material comprise pores extending into said second material.

15

14. A method for implanting a tissue carrier within a physiological system comprising:

20 providing a bioerodible tissue carrier including a first bioerodible polymeric material bonded to a second bioerodible polymeric material;

boring a hole through skin, through underlying cartilage and into a bone;

25

implanting said carrier into said hole such that said first material resides substantially within said bone and said second material resides substantially within said cartilage;  
30 and

covering said skin over said carrier.

-19-

15. The method as recited in claim 14, wherein said implanting step comprises:

5           shaping the outer diameter of said structure to  
            substantially match the internal diameter of  
            said hole; and

            placing said shaped structure into said hole,  
            wherein one end of said structure is  
10           substantially flush with the outer surface of  
            said cartilage.

16. A method for manufacturing a bioerodible tissue  
15   carrier comprising:

            solubilizing a first polymer into a first liquid  
            form having a first viscosity;

20           extracting substantial amounts of liquid from said  
            first liquid form to produce a first modified  
            polymer having pores formed by said extracted  
            liquid; and

25           placing a plurality of passages within said modified  
            polymer.

17. The method as recited in claim 16, further  
30   comprising:

            solubilizing a second polymer into a liquid form  
            having a second viscosity less than said first  
            viscosity;

35           extracting substantial amounts of liquid from said  
            second liquid form to produce a second modified.

-20-

polymer having pores formed by said extracted liquid;

5 adding said second modified polymer to said first modified polymer; and

placing a plurality of passages within said first and second modified polymers.

10

18. The method as recited in claim 16, wherein said solubilizing step comprises dissolving a solid form polymer into a liquid form.

15

19. The method as recited in claim 16, wherein said extracting step comprises:

20 precipitating said first liquid form with a precipitating agent;

pressure curing said first liquid form within a mold.

25

20. The method as recited in claim 17, wherein said adding step comprises placing said second modified polymer into a mold containing said first modified polymer and subsequently bonding said first and second modified polymers together.

30

21. A carrier, comprising:

35 a first material and a second material, the two materials having dissimilar mechanical properties, and the two materials coupled to each other;

-21-

said materials being capable of being placed into a physiological system adjoining at least two dissimilar types of tissue.

5 22. The carrier of claim 21 wherein the first and second materials each have mechanical properties substantially comparable to the mechanical properties of the first and second types of tissue, respectively.

10 23. A tissue support system comprising:

a first material;

a second material coupled to the first material; and

15

said first material and said second material being capable of being implanted into a physiological system with a first type of tissue and a second type of tissue.

20

24. A method for implanting a tissue carrier within a physiological system comprising:

providing a carrier including a first material coupled to a second material; and

25

implanting the carrier such that the first material resides at least partially within the second tissue and said second material resides at least partially within the first material.

30

-22-

25. A method for manufacturing a carrier comprising:

making a first compound into a first form having a  
first viscosity;

5

extracting substantial amounts of compound from said  
first compound form to produce a first modified  
compound.

10






FIG. 1




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET




FIG. 2




FIG. 3

SUBSTITUTE SHEET




FIG. 4

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/01315

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61F2/28; A61L31/00		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61F ; A61L	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	WO,A,8 600 526 (CAPLAN ET AL.) 30 January 1986 see the whole document ---	1-13, 16-23,25
Y	WO,A,8 700 059 (MATERIALS CONSULTANTS OY) 15 January 1987 see abstract; claims 1,2 ---	1-13, 16-23,25
A	EP,A,0 277 678 (STICHTING SCIENCE PARK GRONINGEN) 10 August 1988 see the whole document ---	1-13, 16-23,25
A	WO,A,8 803 417 (MATERIAL CONSULTANTS OY) 19 May 1988 see page 17, column 29 - page 18, column 34; claims 1-8 ---	1,8,16, 21
	-/--	
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
12 MAY 1993	27.05.93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	SANCHEZ Y SANCHEZ J.	

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	FR,A,2 612 392 (AUDION) 23 September 1988	
P,X	--- US,A,5 152 791 (HAKAMATSUKA ET AL.) 6 October 1992 see column 2, line 10 - line 54 -----	21-23,25

Form PCT/ISA/210 (extra sheet) (January 1985)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/01315

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14, 15 and 24  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9301315  
SA 70414

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12/05/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8600526	30-01-86	US-A- 4620327	04-11-86
		AU-A- 4601485	10-02-86
		EP-A- 0188552	30-07-86
WO-A-8700059	15-01-87	AU-A- 6135686	30-01-87
		CA-A- 1277602	11-12-90
		EP-A- 0239577	07-10-87
EP-A-0277678	10-08-88	NL-A- 8700113	16-08-88
		AU-A- 1037688	21-07-88
		JP-A- 63272355	09-11-88
WO-A-8803417	19-05-88	AU-B- 606903	21-02-91
		AU-A- 8235787	01-06-88
		CA-A- 1297795	24-03-92
		DE-A- 3784060	18-03-93
		EP-A, B 0289562	09-11-88
		JP-T- 1501289	11-05-89
		US-A- 5084051	28-01-92
FR-A-2612392	23-09-88	None	
US-A-5152791	06-10-92	JP-A- 3178652	02-08-91

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82